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Summary
Background Rapid on-site diagnosis facilitates tuberculosis control. Performing Xpert MTB/RIF (Xpert) at point of care is 
feasible, even when performed by minimally trained health-care workers, and when compared with point-of-care smear 
microscopy, reduces time to diagnosis and pretreatment loss to follow-up. However, whether Xpert is cost-effective at 
point of care remains unclear.
Methods We empirically collected cost (US$, 2014) and clinical outcome data from participants presenting to primary 
health-care facilities in four African countries (South Africa, Zambia, Zimbabwe, and Tanzania) during the TB-NEAT 
trial. Costs were determined using an bottom-up ingredients approach. Effectiveness measures from the trial included 
number of cases diagnosed, initiated on treatment, and completing treatment. The primary outcome was the 
incremental cost-effectiveness of point-of-care Xpert relative to smear microscopy. The study was performed from the 
perspective of the health-care provider.
Findings Using data from 1502 patients, we calculated that the mean Xpert unit cost was lower when performed at a 
centralised laboratory (Lab Xpert) rather than at point of care ($23∙00 [95% CI 22∙12–23∙88] vs $28∙03 [26∙19–29∙87]). 
Per 1000 patients screened, and relative to smear microscopy, point-of-care Xpert cost an additional $35 529 
(27 054–40 025) and was associated with an additional 24∙3 treatment initiations ([–20∙0 to 68∙5]; $1464 per treatment), 
63∙4 same-day treatment initiations ([27∙3–99∙4]; $511 per same-day treatment), and 29∙4 treatment completions 
([–6∙9 to 65∙6]; $1211 per completion). Xpert costs were most sensitive to test volume, whereas incremental outcomes 
were most sensitive to the number of patients initiating and completing treatment. The probability of point-of-care 
Xpert being cost-effective was 90% at a willingness to pay of $3820 per treatment completion.
Interpretation In southern Africa, although point-of-care Xpert unit cost is higher than Lab Xpert, it is likely to offer 
good value for money relative to smear microscopy. With the current availability of point-of-care nucleic acid 
amplification platforms (eg, Xpert Edge), these data inform much needed investment and resource allocation 
strategies in tuberculosis endemic settings.
Funding European Union European and Developing Countries Clinical Trials Partnership and the South African 
Medical  Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Early screening and diagnosis is a key component of 
tubercu losis control and underpins the post-2015 END TB 
Strategy aimed at substantially reducing the burden of 
disease.1,2 The Xpert MTB/RIF (Xpert) assay is a rapid 
molecular-based test that has consistently shown its 
superior sensitivity over smear microscopy in diagnosing 
pulmonary,3 extrapulmonary,4 and paediatric tubercu-
losis.5,6 As such, it has been endorsed by WHO7 and is 
undergoing a large-scale global rollout.8
However, where Xpert should optimally be placed within 
national tuberculosis programmes (NTPs) re mains 
unclear. Should Xpert, to exploit its portability and user-
friendly format, be situated in centralised labora tories or 
within more peripheral clinics at point of care? WHO 
endorses implementation at centralised health facilities 
(district and subdistrict levels), but this implementation 
limits the potential benefits of Xpert as a rapid diagnostic 
tool. Indeed, later diagnosis and reporting of results, as a 
consequence of centralised placement, can delay clinical 
decisions and hence treat ment initiation.9,10 Moreover, up 
to 40% of patients in tuberculosis endemic areas contribute 
to pretreatment loss to follow-up (ie, they do not return to 
the clinic to start treatment after being informed of a 
positive result).11–13 A large randomised controlled trial14 
showed that placing Xpert at point of care within primary 
care clinics was not only feasible, when performed by a 
minimally trained health-care worker, but significantly 
reduced pretreatment loss to follow-up. Given these con-
sider ations, a strategic and ideological drive has occurred 
to move to point-of-care diagnosis—as occurred with HIV, 
sexually transmitted diseases, and diabetes. Indeed, Xpert 
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is already being used at the point of care in high burden 
clinics, mines, and prisons in countries such as Zimbabwe 
and South Africa.
Although deployment of Xpert at the point of care can 
deliver same-day diagnosis14–16 and other benefits, as out-
lined, the associated diagnostic test and clinical infra-
structure upgrade costs are not insignificant.9,17,18 Thus, 
crucial questions for policy makers, and of prime import-
ance to resource allocation planning, are (1) how does the 
cost of Xpert performed by a minimally trained nurse at 
point of care compare with when performed by a trained 
technician at a centralised laboratory; and (2) is point-of-
care placement of Xpert cost-effective? Although multiple 
studies17,19–26 have examined the economic implications of 
using Xpert in endemic settings, few have focused on 
the costs or cost-effectiveness when deployed at point of 
care,22,25,26 and no studies have calculated cost-effectiveness 
using clinical outcome data obtained from a pragmatic 
real-world prospective study.19–22,24,25 To address these 
questions, we analysed prospectively collected cost and 
clinical outcome data from a large randomised control 
parent trial that recruited patients from primary care 
clinics in four southern African countries (South Africa, 
Zambia, Zimbabwe, Tanzania).14
Methods
Clinical trial design 
We used data obtained from the TB-NEAT trial,14 
which has been described in detail elsewhere. The trial 
was a random ised, two-group, parallel-group study 
of 1502 participants with presumptive tuberculosis re-
cruited from periurban primary health-care clinics located 
in four southern African countries, including South 
Africa (Cape Town and Durban), Zimbabwe (Harare), 
Zambia (Lusaka), and Tanzania (Mbeya). Briefly, patients 
presenting at the clinics with symptoms suggestive of 
tuberculosis between April 12, 2011, and March 30, 2012, 
were recruited into the study and randomly assigned to 
either same-day smear microscopy (n=758; the smear 
microscopy group) or Xpert MTB/RIF performed at the 
point of care (n=744; the Xpert group). Specific inclusion 
and exclusion criteria for patient recruitment can be 
found in the TB-NEAT paper.14 Two spot expectorated 
sputum samples were collected for the index test (smear 
microscopy or Xpert) and mycobacteria growth indicator 
tube liquid culture (BD Diagnostics, Sparks, MD USA). 
Smear microscopy was performed by a qualified 
technician in a laboratory linked to the clinic. In Cape 
Town, smear microscopy was done at a centralised 
laboratory close to the clinic in accordance with South 
African national diagnostic practices. Auramine 
fluorescence smear microscopy was instituted at all study 
sites except Tanzania, which instead used direct light 
microscopy with Ziehl-Neelsen staining. Xpert was done 
by a trained nurse (except in Zimbabwe where national 
policy required Xpert to be performed by a certified 
technician) using a four-module GeneXpert machine that 
was situated at each clinic specifically for the trial. An 
additional Xpert was performed on a stored sputum 
sample at a centralised laboratory (Lab Xpert) by a 
qualified technician, and liquid culture was performed at 
a reference laboratory at each study site. Patients were 
asked to wait until smear microscopy or Xpert results 
became available. If results were positive, patients were 
referred directly to the tuberculosis treatment office in 
the clinic. Patients with negative results were referred for 
routine clinical assessment and chest x-ray. Initiation 
of empirical treatment was decided by the attending 
clinician. Patients were subsequently followed up for 
6 months after diagnosis.
Research in context
Evidence before this study
We searched PubMed for all studies published between 
Jan 1, 2010, and Sept 1, 2018, using the search terms 
“tuberculosis” OR “(TB)” AND (“cost” OR “cost effectiveness”) 
AND (“Xpert MTB/RIF” OR “GeneXpert”). Many studies 
investigated the cost-effectiveness of Xpert MTB/RIF (Xpert) for 
tuberculosis diagnosis in several contexts and settings using 
modelling approaches. Only one South African study estimated 
the cost-effectiveness of Xpert in a real-world context with the 
use of primary economic and clinical data. This study found that 
Xpert was cost neutral and did not improve the 
cost-effectiveness of routine tuberculosis diagnosis. However, no 
published studies assessed the cost-effectiveness of Xpert when 
performed at the point of care with prospectively collected 
clinical and cost-related data.
Added value of this study
This study used empirical cost data nested within a 
randomised controlled trial of point-of-care Xpert versus 
sputum smear microscopy in four African countries, 
suggesting that point-of-care Xpert is a cost-effective option 
for tuberculosis diagnosis in settings willing to pay at least 
US$3820 per additional patient with tuberculosis completing 
treatment. The volume of testing in each clinic was the most 
important determinant of cost and cost-effectiveness of the 
point-of-care Xpert strategy.
Implications of all the available evidence
Data on the cost-effectiveness of Xpert situated at a 
centralised laboratory remain discordant. However, 
the available evidence suggests that, in clinics where volume 
of testing is sufficiently high to offset implementation costs, 
point-of-care Xpert testing is likely to provide good value for 
money in high-burden settings in sub-Saharan Africa.
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Economic evaluation overview
We used clinical and cost data empirically collected from 
each study site to compare the unit cost of point-of-care 
Xpert and Lab Xpert at different test volume capacities 
and to assess the cost-effectiveness of point-of-care 
Xpert com pared with smear microscopy. We performed 
the economic analysis according to well established 
cost-effectiveness analysis guidelines.27,28 A completed 
check list of the essen tial components27 required for 
doing an economic analysis is provided in the appendix.
Measures of cost
We calculated tuberculosis diagnosis and treatment costs 
from the health-care provider perspective in each trial 
country. We calculated the cost per test for smear mi-
croscopy, point-of-care Xpert, Lab Xpert, and chest x-ray. 
At the time of the study, South Africa was using Xpert for 
routine tuberculosis diagnosis within the NTP; we meas-
ured Lab Xpert costs at the remaining study sites (Zambia, 
Zimbabwe, and Tanzania) in the respective clinics, but 
after trial completion (within the context of other ongoing See Online for appendix
Test costs Clinic costs
Smear 
microscopy
Xpert MTB/RIF 
at clinic 
(point-of-care 
Xpert)
Xpert MTB/RIF 
at centralised 
laboratory (Lab 
Xpert)
Chest x-ray Tuberculosis 
screening
HIV testing and 
counselling
Treatment 
initiation
Mbeya, Tanzania
Consumables $1∙24 $11∙10 $11∙10 $1∙80 $0∙00 $1∙27 $0∙00
Staff $0∙97 $0∙75 $0∙58 $0∙66 $2∙68 $3∙56 $2∙28
Equipment $0∙52 $22∙59 $9∙84 $2∙34 $0∙00 $0∙00 $0∙00
Quality control $0∙03 $0∙22 <$0∙01 $0∙00 $0∙00 $0∙00 $0∙00
Overhead $0∙20 $1∙04 $0∙31 $1∙74 $0∙08 $0∙63 $3∙10
Transport $0∙00 $0∙00 $1∙56 $0∙00 $0∙00 $0∙00 $0∙00
Total $2∙96 $35∙70 $23∙40 $6∙54 $2∙76 $5∙46 $5∙37
Lusaka, Zambia
Consumables $1∙05 $11∙03 $11∙03 $0∙00 $0∙00 $0∙74 $0∙00
Staff $0∙33 $1∙02 $0∙57 $0∙47 $4∙91 $2∙06 $1∙81
Equipment $0∙35 $10∙61 $9∙78 $5∙63 $0∙00 $0∙00 $0∙00
Quality control $0∙05 $0∙10 $0∙02 $0∙00 $0∙00 $0∙00 $0∙00
Overhead $0∙12 $1∙98 $0∙16 $0∙21 $0∙36 $0∙29 $0∙24
Transport $0∙00 $0∙00 $1∙63 $0∙00 $0∙00 $0∙00 $0∙00
Total $1∙90 $24∙74 $23∙18 $6∙31 $5∙27 $3∙08 $2∙05
Harare, Zimbabwe
Consumables $1∙29 $10∙72 $10∙31 ∙∙ $0∙00 $1∙19 $0∙00
Staff $0∙31 $0∙48 $0∙51 ∙∙ $1∙88 $1∙32 $1∙70
Equipment $0∙39 $18∙97 $10∙12 ∙∙ $0∙00 $0∙00 $0∙00
Quality control $0∙35 $0∙12 $0∙16 ∙∙ $0∙00 $0∙00 $0∙00
Overhead $0∙21 $0∙65 $3∙52 ∙∙ $0∙48 $0∙17 $2∙59
Transport $0∙00 $0∙00 $5∙95 ∙∙ $0∙00 $0∙00 $0∙00
Total $2∙55 $30∙93 $30∙59 $5∙48* $2∙36 $2∙68 $4∙29
Cape Town, South Africa
Consumables ∙∙ $10∙44 ∙∙ $1∙03 $0∙00 $1∙39 $0∙00
Staff ∙∙ $1∙68 ∙∙ $1∙27 $1∙42 $2∙33 $4∙95
Equipment ∙∙ $13∙51 ∙∙ $8∙34 $0∙00 $0∙00 $0∙00
Quality control ∙∙ $0∙33 ∙∙ $0∙00 $0∙00 $0∙00 $0∙00
Overhead ∙∙ $1∙28 ∙∙ $3∙40 $1∙37 $1∙71 $3∙12
Transport ∙∙ $0∙00 ∙∙ $0∙00 $0∙00 $0∙00 $0∙00
Total $2∙52† $27∙25 $17∙91† $14∙04 $2∙79 $5∙43 $8∙07
All
Total 
(95% CI)‡
$2∙39 
(2∙28– 2∙50)
$28∙03 
(26∙19–29∙87)
$23∙00 
(22∙12–23∙88)
$9∙29 
(7∙94–10∙64)
$3∙34 
(3∙29–3∙38)
$4∙08 
(3∙98–4∙18)
$5∙32 
(4∙90–5∙73)
Costs given in US$, 2014. *X-ray costs in Zimbabwe were taken from the literature32 because empirical data collection was not possible. †The costs of smear microscopy and 
Xpert MTB/RIF performed at a centralised laboratory in South Africa were taken as the per-test charge from the National Health Laboratory Services because empirical data 
collection was not possible. ‡Weighted average of costs across all sites (95%CI), weighted by the number of patients screened at each site.
Table 1: Component and total costs of diagnostic tests and clinic visits in four primary care clinics in southern Africa
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studies). We also assessed the cost per clinic visit for 
tuberculosis screening, HIV testing, and counselling and 
tuberculosis treatment initiation. We estimated the 
weighted mean (weighted by volume of testing) for the 
cost per test and cost per clinic visit across all trial sites. 
We converted local costs to 2014 US$ at exchange rates of 
$1=R9∙65 (South African rand), K5∙35 (Zambia kwacha), 
or TSh1584∙05 (Tanzanian shilling) according to Oanda 
historical exchange rates. At the time of the study, 
Zimbabwe had already adopted US$ as their national 
currency. We adjusted costs to the year of ana lysis as 
necessary using country-specific consumer price indices 
provided by The World Bank. We annualised capital costs 
(building, vehicles, and equipment) at a dis count rate of 
3%. We estimated expected lifeyears of buildings at 50 
years, whereas the expected lifeyears of vehicles and 
equipment ranged from 3–10 years depending on their 
frequency of replacement as indicated by staff. Further 
details on costing methods can be found in the appendix.
Measures of effectiveness
We derived effectiveness measures from clinical out-
comes reported in the TB-NEAT trial.14 We reported 
outcomes for each individual trial site and subsequently 
combined for all sites. We only included participants 
with a valid culture result in the analysis. The measures 
of effectiveness calculated in each study group (smear 
microscopy and Xpert) included the number of culture-
positive tuberculosis cases: (1) diagnosed by the index 
test, (2) initiating antituberculosis treatment, (3) initi-
ating antituberculosis treatment on the same day as diag-
nosis, (4) completing antituberculosis treatment, and 
(5) having improved morbidity (measured by a numerical 
tubercu losis score). Completing antituberculosis treat-
ment refers to patients who completed a full 6-month 
course of antituberculosis treatment and excluded those 
who were not treatment-adherent, who had died, or 
who were lost to follow-up (participants started on anti-
tuberculosis treatment who were not retained in the 
study). Improved morbidity refers to patients who started 
antituberculosis treatment and showed a 25% or more 
decrease in the well validated tuberculosis score at the 
end of treatment compared with baseline (see TB-NEAT14 
and Wejse and colleagues29 for more details on tubercu-
losis score determination). The TB-NEAT trial was not 
powered to examine differences in mortality between the 
two groups. As such, this measure was not included in 
our analysis. We also reported effectiveness measures 1–5 
as a proportion of all individuals clinically suspected of 
having tuberculosis based on symptom screening. 
Out comes were normalised to 1000 people with sus-
pected tuberculosis screened in each study group. 
Incremental effectiveness (per 1000 people with sus-
pected tuberculosis screened) was also reported. We used 
incre mental costs and outcomes to calculate the incre-
mental cost-effectiveness ratio (ICER) for selected out-
comes among culture-positive cases. Further details 
regarding assumptions used in the analysis can be found 
in the appendix.
Sensitivity analysis
We did univariate sensitivity analyses to calculate the 
effect of varying specific parameter inputs on the cost per 
test of point-of-care Xpert and the incremental cost 
per culture-positive patient starting treatment. We also 
did a probabilistic sensitivity analysis to calculate the un-
certainty around ICERs given the challenges in esti-
mating their confidence intervals.30 This analysis involves 
simultaneously varying cost and effectiveness parameter 
inputs with the use of 10 000 randomly sampled estimates 
drawn from their defined probability distributions. We 
confirmed that 10 000 simulations would be sufficient 
for model convergence around the uncertainty using 
a previously published approach.31 Briefly, we generated 
ICERs for each outcome using two separate sets of 
10 000 randomly sampled estimates to ensure that the 
mean values of each set of simulations fell within 
the 95% CI range of the corresponding set (appendix). 
We also doubled the number of simulations from 
10 000 to 20 000 to confirm the width of the 95% CIs 
were effectively unchanged (appendix). We calcu lated 
ICERs for each estimate and used them to construct a 
cost-effectiveness acceptability curve to establish the 
Figure 1: Estimated unit cost per Xpert test
Costs (US$, 2014) estimated according to annual test volume either at the clinic (point-of-care Xpert; dashed lines) 
or central laboratory (Xpert Lab; solid lines) for each individual study site. The overall weighted average of all sites is 
shown by the grey lines. The cost per Xpert test on the y-axis is expressed on a logarithmic scale. The observed 
annual number of Xpert tests done at the laboratory (circles) and at the clinic (diamond) in each of the four study 
sites are indicated. The Xpert Lab is not presented for South Africa as no empirical cost data were collected for this 
site. For individual and all sites, the observed annual testing frequency was greater at the laboratory compared with 
the clinic, resulting in a lower Xpert Lab unit cost. However, if the annual number of Xperts performed annually were 
the same for a given site, the unit cost of point-of-care Xpert would be less than Xpert Lab. Xpert=Xpert MTB/RIF.
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probability that point-of-care Xpert would be considered 
cost-effective compared with smear microscopy over a 
range of willingness-to-pay thresholds.
Statistical analysis was done using GraphPad Prism 
version 6.0 and Microsoft Excel 2016.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The cost per Xpert assay performed at the clinic (ie, 
point-of-care Xpert) and at a centralised laboratory (ie, 
Lab Xpert) was calculated at each study site to allow 
for cost com parisons at different levels of programmatic 
implemen tation. Component costs included con sum-
ables, staff, equip ment, overheads, quality control, and 
transport. Under observed conditions, the cost of point-
of-care Xpert ranged from $24∙74 in Zambia to $35∙70 
in Tanzania, whereas Lab Xpert costs ranged from 
$17∙91 in South Africa to $30∙59 in Zimbabwe (table 1). 
Across all sites, the weighted mean Lab Xpert unit cost 
was lower than for the point-of-care Xpert ($23∙00 
[95% CI 22∙12–23∙88] vs $28∙03 [26∙19–29∙87]). Under 
observed conditions, Lab Xpert test volumes were 
2–5 times higher than the point-of-care Xpert at any 
given testing facility. Point-of-care Xpert became less 
costly than Lab Xpert under the assumption that 
annual test volume estimates were equiva lent (figure 1; 
appendix). Unit test and clinic costs, including the cost 
breakdown, are reported in table 1.
Figure 2A and 2B (appendix) show differences in 
clinical outcomes comparing point-of-care Xpert to 
smear mi croscopy, both among culture-positive patients 
and symp tom atic patients. For example, when comparing 
point-of-care Xpert to smear microscopy, the difference 
in culture-confirmed tuberculosis cases starting anti-
tuberculosis treatment was 24∙3 cases per 1000 people 
screened (95% CI –20·0 to 68·5) and in those com-
pleting antituberculosis treatment was 29∙4 cases per 
1000 people screened (–6·9 to 65·6). In terms of incre-
mental costs, point-of-care Xpert was more expensive 
than smear microscopy, with costs ranging from 
$28 503 per 1000 people screened in Zimbabwe to 
$53 280 in Tanzania. Across all study sites, the incre-
mental cost amounted to $35 528 per 1000 people 
screened (27 053–40 024) and was strongly associated 
with the unit cost of point-of-care Xpert (figure 2C).
The cost-effectiveness of point-of-care Xpert for the indi-
vidual and combined study sites is reported as the 
incre mental cost per selected outcome among culture posi-
tive tuberculosis cases (table 2). Cost-effectiveness esti-
mates varied widely across study sites, with cost per 
treatment initiation ranging from $984 in South Africa to 
$2699 in Zambia (weighted mean of $1464 per treat-
ment initiation) and cost per treatment completion ranging 
from $465 per treatment completed in Zambia to $8485 in 
South Africa (weighted mean $1211 per treatment com-
pleted). We also compared our cost-effectiveness estimates 
to other estimates of tuberculosis inter ventional strategies, 
in terms of disability-adjusted life-years (DALYs) averted, 
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Figure 2: Differences in clinical outcomes comparing point-of-care Xpert to 
smear microscopy in culture-positive patients and symptomatic patients
Error bars indicate 95% CIs. All outcomes and costs are normalised to 1000 patients 
in each study group. (A) The estimated incremental outcomes for patients 
ultimately found to have culture-confirmed tuberculosis. (B) Corresponding 
outcomes in all patients. (C) The estimated incremental costs (US$, 2014); 
estimates are shown under the assumption that the unit cost of Xpert at all sites 
can be doubled or halved. Xpert=Xpert MTB/RIF.
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from the published literature (appendix).24,33,34 In this com-
parison, our baseline cost-effectiveness estimates, in most 
cases, decreased to less than 3 times the gross domestic 
product (GDP) per capita per DALY averted in each country.
In one-way sensitivity analysis, the expected useful life, 
purchase price, and annual test volume of the Gene Xpert 
machine had the greatest influence on the point-of-care 
Xpert unit cost (figure 3A). A similar pattern was ob served 
on the incremental cost per treatment initiation and treat-
ment completion among culture-positive patients. How-
ever, the largest influence on cost per treat ment initiation 
was the proportion of culture-positive patients starting 
treatment. In the point-of-care Xpert group of the trial, 
Tanzania Zambia Zimbabwe South Africa All sites*
Diagnosed by index test $4254 Point-of-care Xpert† $1675 $1373 $4186
Starting treatment $1554 $2699 $1685 $984 $1464
Starting treatment on 
same day as diagnosis
$1107 $785 $399 $46 $561
Completing treatment $521 $465 $4309 $8485 $1211
Improved morbidity $508 $2024 $1710 $3101 $1918
Costs are in $US, 2014. *Weighted average of costs and outcomes across all sites, weighted by the number of patients 
screened and number of clinical outcomes observed at each site. †Indicates that point-of-care Xpert was both more 
expensive and less effective than smear microscopy for that particular clinical outcome.
Table 2: Incremental cost-effectiveness ratios, defined as the incremental cost per selected clinical 
outcome among culture positive cases
0 20 25 30 35 40 45 50 55 60
ELY of GeneXpert machine (1–5)
Number of Xpert MTB/RIF tests run annually (568–1136)
 Cost of GeneXpert machine (8750–35 000)
 Cost of Xpert cartridge (4·99–19·96)
Number of GeneXpert modules replaced annually (0–4)
 Discount rate (1–10)
Time (min) to perform Xpert (4·56–18·24)
ELY of building infrastructure (25–75)
Cost per point-of-care Xpert assay (US$)  
750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 3750
Proportion of culture-positive patients starting treatment (85–100)
ELY of GeneXpert machine (1–5)
Number of Xpert tests run annually (568–1136)
Cost of GeneXpert machine (8750–35000)
Cost of Xpert cartridge (4·99–19·96)
Number of GeneXpert modules replaced annually (0–4)
 Discount rate (1–10)
Time (min) to perform Xpert (4·56–18·24)
ELY of building infrastructure (25–75)
Incremental cost per treatment initiation among culture-positive patients (US$)
500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500
Proportion of culture-positive patients completing treatment (50–80)
Proportion of culture-positive patients who default or LTF (15–40)
ELY of GeneXpert machine (1–5)
Number of Xpert tests run annually (568–1136)
Proportion of culture-positive patients starting treatment (80–100)
Cost of GeneXpert machine (8750–35000)
Cost of Xpert cartridge (4·99–19·96)
Number of GeneXpert modules replaced annually (0–4)
 Discount rate (1–10)
Time (min) to perform Xpert (4·56–18·24)
ELY of building infrastructure (25–75)
Incremental cost per treatment completion among culture-positive patients (US$)
$29·56 
$29·22 
$28·94 
$27·21 
$24·64 
$23·64 
$47·61 
$54·14 
$29·88 
$30·45 
$32·30 
$36·89 
$39·61 
$41·59 
$20·63 
$24·73 
$1458 
$1442 
$1437 
$1360 
$1254 
$1213 
$2200 
$2469 
$3561 
$1465 
$1493 
$1542 
$1758 
$1870 
$1952 
$1089 
$1257 
$954 
$1213 
$1193 
$1186 
$1124 
$1037 
$1003 
$1954 
$1819 
$2042 
$710 
$3445 
$1205 
$1235 
$1285 
$1454 
$1547 
$1614 
$1069 
$900 
$1040 
$2207 
$684 
A
B
C
High input value
Low input value
Figure 3: Univariate sensitivity analysis
Tornado diagrams showing the effect of changing individual cost parameters on the cost (US$, 2014) per Xpert assay performed at the point of care (A), the incremental 
cost per treatment initiation (B), and the incremental cost per treatment completion among culture-positive patients across all sites (C). Low and high estimates of each 
input parameter are shown in parentheses on the left side of each figure. ELY=expected life years. LTF=lost to follow up. Xpert=Xpert MTB/RIF.
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91% of culture-positive patients started treatment. If this 
proportion fell to 85%, then the estimated incremental 
cost per treatment initiation increased from $1464 to 
$3561 (figure 3B). Similarly, reducing the proportion 
of culture-positive patients completing treatment from 
60% to 50% increased the estimated cost per treatment 
completion from $1211 to $3445. A similar pattern was 
also observed if the number of patients who were lost to 
follow-up was varied (figure 3C).
Figure 4 shows the willingness-to-pay thresholds at 
which point-of-care Xpert would be preferred over smear 
mi croscopy across 10 000 probabilistic simulations. 
Assuming that a 90% probability of cost-effectiveness 
might make an effective decision threshold, point-of-care 
Xpert would be preferred at this threshold in settings 
willing to pay $9450 per culture positive patient diag-
nosed, $4450 per patient starting treatment, $1600 per 
patient starting treatment on the same day as diagnosis, 
$3820 per patient completing treatment, or $5840 per 
patient with improved morbidity. Willingness-to-pay 
thresholds at other cost-effectiveness probability esti-
mates are shown in the appendix.
Discussion
The primary findings of this economic evaluation, nested 
within a clinical trial across four Southern African 
coun tries, is that point-of-care Xpert, while more costly 
than smear microscopy, is likely to be cost-effective (in 
>90% of simulations) in settings willing to pay at least 
$4500 per treatment initiation or $3800 per treatment 
completion among culture-positive patients. High test 
volume capacity at primary care clinics is probably 
necessary for Xpert point-of-care placement to be eco-
nomically feasible in many settings.
Few studies have estimated the economic effect of 
implementing Xpert at the point of care22,25,26 and all have 
used modelling analyses rather than prospectively obtained 
trial data to assess cost-effectiveness.19,20,24,25,35 In most of 
these modelling studies, Xpert was cost-effective either as 
a full replacement19,24,25,35 or in conjunction with other diag-
nostic tests20,21 compared with the standard of care (smear-
microscopy). However, some of these studies did not 
incorporate empirical treatment and thus might have over-
estimated the effectiveness of Xpert.24,25 Our estimates of 
cost-effectiveness account for levels of empirical treatment 
observed in the TB-NEAT trial and require fewer modelling 
assumptions than these previous analyses but might, 
there fore, underestimate the effectiveness of point-of-care 
Xpert by not explicitly accounting for effects on secondary 
transmission. Conversely, clinical trials can provide direct 
and real-world data on patient important outcomes related 
to Xpert implementation. For example, the XTEND trial15 
assessed the effect of Xpert relative to smear microscopy 
on patient morbidity and mortality when placed at central 
laboratories within the context of the South Africa national 
Xpert rollout. Similar to TB-NEAT, no significant differ-
ences were observed in terms of patient morbidity or 
mortality. A subsequent follow-up cost-effectiveness ana-
lysis showed that the South African Xpert rollout was cost 
neutral and failed to improve the cost-effectiveness of 
tubercu losis diagnosis, probably due to the trial finding no 
benefits to mortality.23 Conversely, in our study we used 
clin ical endpoints from the TB-NEAT trial rather than 
mortality or health utility (eg, DALYs as more direct meas-
ures of effectiveness). We estimated that, relative to smear 
microscopy, point-of-care Xpert is likely to cost $1464 per 
treatment initiation and $1211 per treatment completion 
among patients with culture-confirmed tubercu losis.
In deciding whether point-of-care Xpert would be 
cost-effective, there is no consensus on appropriate 
Figure 4: Cost-effectiveness acceptability curves for selected incremental cost-effectiveness ratios
The probability of point-of-care Xpert, relative to smear microscopy, being cost-effective was plotted as a 
function of willingness to pay per culture-positive patient diagnosed by the index test (A), starting treatment 
(B), starting treatment on same day as diagnosis (C), completing treatment (D), and experiencing improved 
morbidity for all sites combined (E). The arrow indicates the willingness-to-pay threshold, at which the 
probability of cost-effectiveness is 90%. Xpert=Xpert MTB/RIF.
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willingness-to-pay thresholds, and the use of generic 
thresholds have been largely criticised.36–38 Cost-effective-
ness thresholds provide no information on affordability 
and do not have the disease-specific context in which 
scale-up of point-of-care Xpert could have major impli-
cations on resource allocation within the NTP. 
Nonetheless, a commonly used metric for highly cost-
effective interventions is the per-capita GDP (or gross 
national income) per DALY averted (or 3 times this value 
for cost-effective interventions). To keep our analysis 
faithful to trial-measured outcomes (with a minimum of 
modelling assumptions), we did not measure outcomes in 
terms of DALYs averted. However, we did compare our 
results to those of other model-based economic evaluations 
from which a ratio could be calcu lated of clinical outcomes 
(as calculated in this study) to DALYs averted 
(appendix).24,33,34 Our estimates in these com parisons were 
substantially less favourable toward point-of-care Xpert 
(eg, incremental cost-effectiveness ratio 10 times higher 
than reported by Vassall and col leagues),24 probably 
because our estimates incorporate the levels of empirical 
treatment observed in the TB-NEAT trial. Nevertheless, 
our estimates of point-of-care Xpert cost-effectiveness in 
most cases come below a threshold of 3 times per-capita 
GDP per DALY averted, suggesting cost-effectiveness of 
this intervention according to this classical willingness-to-
pay threshold. These results do not speak to the 
affordability of point-of-care Xpert under existing budget 
constraints, but they do suggest that the cost-effectiveness 
of point-of-care Xpert is likely to be at least equivalent to 
that of many other interventions that have been 
characterised as cost-effective in the scientific literature up 
to now.
Another useful metric to assess cost-effectiveness and 
willingness to pay is the potential health gains if provided 
with a fixed monetary sum. For example, if an additional 
$10 000 was provided to the NTP for the Xpert point-of-care 
strategy, the expected gains over smear microscopy would 
be an additional four tuberculosis cases diagnosed, 12 cases 
starting treatment, 30 cases starting same-day treatment, 
and 14 cases completing treatment (appendix). Thus, 
policy makers can directly compare these values to other 
tuberculosis diagnostic strategies to assess the relative 
expected value of investment in point-of-care Xpert.
The TB-NEAT trial showed an increase in the number 
of Xpert-positive culture-negative individuals that were 
placed on treatment. Conversely, a Brazilian study35 
showed a reduction in these Xpert false positives (with 
culture as a gold standard) compared with smear mi-
croscopy. Such discrepancies between Xpert and culture 
could represent false-negative culture results but might 
also reflect false-positive Xpert results due to residual 
Mycobacterium tuberculosis DNA, particularly in people 
previously (and successfully) treated for tuberculosis.39 If 
some of these individuals who start treatment do indeed 
represent Xpert false-positives, it will be important to 
establish the extent of such Xpert-based overtreatment 
in various settings because the cost of such overtreatment 
($113 per patient in our analysis) is not inconsequential.
The TB-NEAT study also showed much higher smear 
microscopy-based empirical treatment decisions compared 
with Xpert and probably explains why no incremental 
morbidity benefit was observed in the trial. To the extent 
that such empirical diagnoses represent people without 
underlying tuberculosis, the true cost-effectiveness of 
point-of-care Xpert might be even more favourable than 
reported here.
This study also speaks to the cost implications of 
placing Xpert at the point of care versus a centralised 
facility. In our analysis, test capacity was a major 
influence driving the unit cost of Xpert. However, despite 
annual test volumes being 2–5 times higher when Xpert 
was positioned in the laboratory, point-of-care Xpert was 
only slightly more expensive on a per-test basis in 
some settings due to reductions in sample transport and 
overhead costs (table 1). Additionally, the variation in 
Lab Xpert test costs across study settings reflects the 
different laboratory setups at each site. For example, 
more GeneXpert machines were in use at the centralised 
laboratory in Zambia accounting for the higher Lab Xpert 
costs at that site.
In most countries, Xpert has been positioned at 
subdistrict level laboratories within the NTP rather than 
at the peripheral level, probably due to the financial and 
logistical limitations of point-of-care placement. A 2011 
South African study17 projected that national implemen-
tation of Xpert at the point of care would cost 51% more 
than lab placement, equivalent to an estimated $36 million 
per year. This cost represents a major hurdle to point-of-
care placement, especially in other high burden countries 
where NTP budgets are under severe financial con-
straints.40 However, these costs should be interpreted 
with in the overall context of the economic effect of 
tubercu losis; one report41 estimated that, over the next 
15 years, economic losses due to tuberculosis would 
amount to about $300 billion in the African region 
(equating to about 2–3% of the GDP in the case of some 
African countries, including South Africa) and close to 
$1 trillion globally. The cost implications on patients can 
also be substantial, especially in low-income countries 
where tuberculosis disease can consume close to 60% of 
an individual’s income.42 Additional concerns of point-of-
care placement include the need for a stable electricity 
supply, temperature control, and adequate storage facil-
ities.9,18 However, placement of Xpert at centralised 
facilities diminishes its potential to improve patient out-
comes.9 One potential solution might involve targeting 
point-of-care Xpert placement at specific primary care 
facilities where cost and health benefits can be maximised. 
For example, point-of-care implementation of Xpert 
might first be prioritised to clinics (1) in tuberculosis 
hotspots—ie, periurban slums where the disease burden 
is high, (2) where transportation of samples to central 
labora tory facilities is difficult and delays in result 
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reporting are common, (3) where empirical treatment 
initi ation is uncommon, and (4) where the incidence of 
drug resistance and rates of loss to follow up are high. 
Any implementation strategy will need to be assessed in 
the context of newer Xpert technologies, such as the more 
point-of-care-friendly Xpert Edge instrument (recently 
released and uses the more sensitive Xpert Ultra cart-
ridge),43 and point-of-care molecular platforms in develop-
ment (eg, QuantuMDx. etc).44
Our study had several limitations. First, we did not 
account for rifampicin (RIF) resistance detection, a major 
advantage of Xpert, in our analysis. The parent trial was 
not powered for detection of drug resistance, and the 
additional effectiveness gained by RIF resistance de-
tection is not directly comparable to smear microscopy 
without incorporating another method of drug resistance 
testing, such as line probe assay, which was not per-
formed in the study. Incorporation of RIF resistance de-
tection might make Xpert more cost-effective by reducing 
the time to treatment in positive cases but might also 
favour smear microscopy because of the possibility for 
false-positive diagnosis of RIF resistance by Xpert. 
Second, our results are difficult to directly compare with 
those that used single utility metrics, such as DALYs. 
However, we chose to compare costs using hard data and 
real-world clinical outcomes (obtained from several 
settings) rather than to estimate a measure (eg, DALYs), 
which requires extensive assumptions about the down-
stream consequences of a diverse array of clinical out-
comes based on sparse data. We also did not attempt to 
estimate effects on secondary transmission for similar 
reasons; thus, our findings, like for resistance detection, 
might be biased against point-of-care Xpert, which 
significantly shortened time to diagnosis in the trial. 
Third, economic evaluation within the context of a clin-
ical trial has inherent limitations. Although able to 
provide direct data in specific settings compared with 
modelling, resource use and patient recruitment is often 
restricted to the selection criteria of the trial protocol.45 
However, TB-NEAT was designed with pragmatic 
implemen tation in mind, which might mitigate this 
concern to some degree, and empirical cost data was 
collected in a standardised way from multiple high-
burden settings, which might not have been possible 
outside the context of a clinical trial. The cost of Lab Xpert 
used in our analysis (figure 1) was taken from the 
National Health Laboratory Service (NHLS) in South 
Africa but might be lower than if estimated with the use 
of empirically collected cost data.46 The NHLS Lab Xpert 
cost estimate was chosen because it represents the cost 
charged to the South African government and thus 
represents the actual cost incurred from the health-care 
provider perspective. Several other studies47–49 have used 
this estimate for similar reasons. Finally, some limi-
tations were also related to measurement uncertainty 
of costs and outcomes. The large differences in incre-
mental cost-effectiveness observed between the different 
study sites was primarily driven by differences in 
effective ness measures. However, these differences 
should be interpreted with caution because of the low 
recruit ment number at any given site (eg, wide 95% CIs 
were reported for patient outcomes in Tanzania) and that 
the TB-NEAT clinical trial was not powered to detect 
differences across the various study site.
In summary, we have estimated the cost-effectiveness 
of implementing Xpert at the point of care in 
four different African settings. Overall, our results 
indicate that a point-of-care-based Xpert can offer good 
value for money relative to other tuberculosis diagnostic 
strategies, though the cost-effectiveness of this strategy 
is likely to be even higher given that transmission 
reduction and drug resistance detection were not 
factored into the analysis. These findings will facilitate 
decision making about public health strategy and 
resource allocation by NTPs so that cost savings and 
health benefits can be maximised.
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